Biotech

All Articles

Ascendis' dwarfism medication hits in stage 3, endangers BioMarin

.Ascendis Pharma has actually emerged as a potential danger to BioMarin's Voxzogo, stating period 3 ...

Despite ph. 3 miss out on, Alkeus sees path ahead of time for eye health condition property

.Though Alkeus Pharmaceuticals' oral eye illness possession neglected to considerably minimize geogr...

Kairos goes social along with $6M IPO to finance trials of cancer medication

.With a trio of biotechs attacking the Nasdaq on Friday, it was actually simple to skip a smaller-sc...

Vaccine and Keytruda combo helpful in squamous tissue carcinoma

.Immune gate inhibitors are actually the superheroes of cancer cells treatment. Medications like Bri...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings as ...

Regeneron's Opdualag opponent reveals 57% response rate

.Regeneron is back along with long-term consequence for its LAG-3 inhibitor and also PD-1 prevention...

AstraZeneca articles information on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early take a look at the functionality of its own internal antibody-drug ...

iTeos- GSK's TIGIT star presents relevant enhancement

.After announcing a period 3 launch based on favorable midstage end results, iTeos and also GSK are ...

More collaborative FDA may speed up rare illness R&ampD: record

.The FDA ought to be extra open and collective to release a surge in approvals of rare condition med...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It's an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bica...